Omriclone Becomes the First Xolair Biosimilar Approved in Japan

"Lineup Expanded to Asthma and Ophthalmic Diseases with Approval of Two New Products"

Celltrion has received marketing approval in Japan for two biosimilars: an allergy treatment and an ophthalmic treatment.

Celltrion company logo image. Celltrion

Celltrion company logo image. Celltrion

View original image

On March 27, Celltrion announced that it has obtained marketing approval from Japan’s Ministry of Health, Labour and Welfare for the omalizumab biosimilar “Omriclone” and the aflibercept biosimilar “Eydengelt.” Omriclone has been approved for all indications of the original drug, including bronchial asthma, chronic urticaria, and seasonal allergic rhinitis.


Omriclone is the first Xolair biosimilar to be approved in Japan. It has been approved in two formulations: pre-filled syringe and auto-injector. The original drug, Xolair, recorded approximately 7.6 trillion KRW in global sales last year.


Eydengelt has been approved for major ophthalmic indications such as macular degeneration and diabetic macular edema, with both vial and pre-filled syringe formulations. The original drug, Eylea, achieved global sales of about 8.5 trillion KRW.


With this approval, Celltrion has expanded its product portfolio from a focus on autoimmune diseases and oncology to now include ophthalmology and allergy treatments.


Celltrion has continued to increase its market share in Japan through its existing biosimilar products. According to pharmaceutical market research firm IQVIA, the breast cancer treatment “Herzuma” holds about a 76% market share in Japan, maintaining the top position for trastuzumab prescriptions. “Begzelma” currently has a 58% share. The autoimmune disease treatments “Remsima” and “Yuflyma” also hold 43% and 17% market shares, respectively.



A Celltrion official stated, “We plan to further expand our product lineup in Japan through the early market entry of these newly approved products.”


This content was produced with the assistance of AI translation services.

© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.

Today’s Briefing